Celularity, Inc. (NASDAQ:CELU) Shares Shorted: Short Interest Down 52.3% in September

Celularity, Inc. (NASDAQ:CELU) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 391,276 shares, a drop of 52.3% from the September 15th total of 821,020 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 154,929 shares, the short-interest ratio is currently 2.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Celularity Trading Down 7.7%

NASDAQ CELU traded down $0.11 during trading hours on Wednesday, hitting $1.31. 47,821 shares of the company’s stock traded hands, compared to its average volume of 1,363,318. The business’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.03. The firm has a market capitalization of $42.51 million, a P/E ratio of -0.48 and a beta of 0.77. Celularity has a 52 week low of $0.56 and a 52 week high of $2.55.

Celularity (NASDAQ:CELU) last announced its earnings results on Tuesday, September 29th. The company reported $0.02 EPS for the quarter. The business had revenue of $3.85 million for the quarter.

Institutional Investors Weigh In On Celularity

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. acquired a new stake in shares of Celularity, Inc. (NASDAQ:CELU) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity accounts for about 0.8% of C V Starr & Co. Inc.’s portfolio, making the stock its 4th largest holding. C V Starr & Co. Inc. owned about 2.64% of Celularity as of its most recent filing with the SEC. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.